This platform was built from metadata aggregated by the Chaire AgingUP! team from Université Paris Cité, using twenty years of academic research on health economics and health policy analysis. It combines large-scale public datasets, peer-reviewed research methods and advanced analytics to provide decision-makers with actionable insights on medicines, healthcare systems and market access. Originally developed within an academic environment, the platform translates rigorous research into practical tools designed to support evidence-based decision making. The underlying databases and analytical frameworks have been developed through collaborations with leading academic institutions and international organizations, and are continuously enriched through ongoing research activities. The objective of this research project is to explore the dynamics of the US pharmaceutical market through empirical analyzes. It builds on the following working paper: Rapp T., “Exploring Retail Acquisition Price Convergence After ANDA Market Entry in the United States, 2013–2026” (Université Paris Cité, LIRAES & Chaire AgingUP!; Sciences Po Paris, LIEPP).
Where the prices come from. Every price on this platform is the NADAC (National Average Drug Acquisition Cost). It measures what retail / community pharmacies actually pay to buy a drug from wholesalers and manufacturers — a pharmacy acquisition cost. It is surveyed monthly from pharmacy invoices and published by CMS. It is a real transaction price upstream of the patient, not a list price.
What the NADAC price is — and is not. The NADAC is the retail pharmacy acquisition channel only: it excludes hospital / inpatient and 340B pricing, commercial / private-insurer negotiated prices, patient out-of-pocket cost, and manufacturer list price (WAC). Medicare Part D spending and Medicare coverage decisions are included as dedicated modules, but the NADAC price itself is not a Medicare or net (post-rebate) price.
Where the volumes come from. Prescription and unit volumes are from Medicaid State Drug Utilization Data (SDUD), a large but partial slice of total US demand (Medicaid beneficiaries only). They show structure and trends, not the whole market.
The aggregated econometric base. The full-market econometric results (event study and price-convergence regressions) reproduce the author's peer-reviewed research: Rapp T., “Exploring Retail Acquisition Price Convergence After ANDA Market Entry in the United States, 2013–2026” (Université Paris Cité, LIRAES & Chaire AgingUP!; Sciences Po Paris, LIEPP).
Data sources mobilised. All public, all chained at the molecule level: NADAC retail acquisition prices (CMS) · Drugs@FDA approvals & submissions and the Orange Book patents/exclusivities (FDA) · Medicaid State Drug Utilization Data (CMS) · Medicare Part D Spending by Drug (CMS) · Medicare Coverage Database — national & local coverage determinations and public comments (CMS) · Open Payments industry-to-physician transfers (CMS) · NPPES NPI registry (CMS) · ClinicalTrials.gov trials & investigators (NIH) · FAERS adverse-event reports and Structured Product Labeling (FDA) · OpenAlex scholarly catalogue.